Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Needham Starts Axsome at Buy, Cites Revenue Growth Potential
Axsome Therapeutics Price Target Maintained With a $131.00/Share by RBC Capital
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $131
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Needham Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $130
Express News | Axsome Therapeutics Inc : Needham Initiates Coverage With Buy Rating; Target Price $130
Axsome Therapeutics' AXS-05 Shows Promising Results in Treatment-resistant Depression
Decoding 9 Analyst Evaluations For Axsome Therapeutics
B of A Securities Maintains Neutral on Axsome Therapeutics, Lowers Price Target to $95
Axsome Therapeutics Analyst Ratings
Express News | Axsome Therapeutics Inc : BofA Global Research Cuts Price Objective to $95 From $97
Citi Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Therapeutics: Stable Auvelity Growth and Coverage Amid New GPO Contract
Axsome Therapeutics' Auvelity Poised for Growth Despite Temporary Prescription Dip
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
Express News | Axsome Therapeutics Inc : RBC Raises Target Price to $131 From $130